Press Releases for SNY

Press Releases
Global Health Ventures Inc. (OTCBB: GHLV) Commences an Investment Road Show, Starting in Montreal, Quebec and Then Presenting in London, England
BenchmarkJournal.Com Free Analyst Review for AU, DOV, HSP, SNY, TCK and S
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Video: 'Sounds of Pertussis' Campaign Urges Adults to Take Action During National Immunization Awareness Month
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
National Transitions of Care Coalition Creates a Work Group on Health Information Technology (HIT)
Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Sanofi-aventis to Acquire Merck's Interest in Merial
FDA Approves Sculptra(R)Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
Sanofi-aventis Announces Second Quarter 2009 Results
Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Earnings for Q2 2009
MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States
Sanofi-Aventis May Place Alnwick Research Center Up for Sale, an Industrial Info News Alert
Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza
BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer
Expert Statement Issued about Lantus(R) Following Recent Publications in Diabetologia
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
FDA approves new fibrillation drug
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
Photos: Soccer Hall of Famer Marcelo Balboa Encourages Men to 'Team Up Against Prostate Cancer'
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
New Pooled Analysis Found Lantus(R) Reduced A1C and FBG Levels in Adults Over 65 with Type 2 Diabetes Compared to Those Treated with NPH
Leading Pharmaceutical Company sanofi-aventis Chooses Cegedim Dendrite as Global Partner
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Sanofi-aventis U.S. Announces Settlement of Medicaid 'Best Price' Investigation
Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Compressions dans les regimes de soins de sante : peu indiquees en periode de recession
Recession not the time to trim health benefits
Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine
Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on Earnings for Q1 2009
BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
Zacks Analyst Blog Highlights: Sanofi-Aventis, Johnson & Johnson, AIG, Palm, Inc., And Research In Motion
FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S.
Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin'
Sanofi-aventis Partners With the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Sanofi-aventis Video Q&A : New CEO Chris Viehbacher Comments on Earnings and Outlook
Zacks Analyst Blog Highlights: DIRECTV, AT&T, Verizon, Sanofi-Aventis and Everest Re Group, Inc.
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation - Feb 12 2009 10:03AM
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation - Feb 11 2009 7:09PM
Jean-Pierre Lehner Appointed Chief Medical Officer
Laurence Debroux Appointed Chief Strategic Officer (CSO)
Sanofi-aventis Delivers 2008 Results Above Guidance
Sanofi-aventis Partners with the African American Community in Newark to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
Zacks Analyst Blog Highlights: Eli Lilly & Co., Bristol-Myers, Sanofi-Aventis, Wells Fargo and Morgan Stanley
Zacks Analyst Blog Highlights: Sanofi-Aventis, Pfizer, Wyeth, Broadcom Corp. And Citigroup.
BenchmarkJournal.Com (Complimentary) Analyst Review for BMY, SNY, RTN and WYN
New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes
Zacks Bull & Bear of the Day Highlights: InterDigital, Overstock.Com, Sanofi-Aventis, Bristol-Myers Squibb and Biogen Idec
Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment
Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
A Shot in the Arm to Fight Skin Cancer - PR Newswire
A Shot in the Arm to Fight Skin Cancer - CNW
Sanofi-aventis Canada Inc. Licenses I-many ContractSphere to Manage Complex Pharmaceutical Contracts
Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Pfizer, St. Jude Medical, Inc. And eBay Inc.
Sanofi-aventis and Novozymes Announce a Development and Commercialization Collaboration for an Innovative Antibiotic
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® Patent Infringement Case
Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Eli Lilly and Company Joins SAFE-BioPharma Association
Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older - Oct 27 2008 10:11AM
High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older - Oct 26 2008 1:08PM
Diabetes 'Champions' Share their Stories through Circle of Champions Campaign
State of Diabetes in Philadelphia: Greater Philadelphia Diabetes Coalition Releases Report
TB Alliance Enters into Collaboration with sanofi-aventis to Fight Tuberculosis
New Findings Spark 'What You Do Matters' Call to Action to Educate Women on Reducing Cancer Risks
National Transitions of Care Coalition Conducted Information Exchange on the Issue of Transitions of Care
Olympic Gymnasts Promote Cancer Awareness Oct. 2 at the Steeplechase Cancer Center
RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment
FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old - Sep 29 2008 3:27AM
sanofi-aventis U.S. Named a 2008 100 Best Company by Working Mother Magazine
FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old - Sep 23 2008 4:01AM